CN1188406C - Cattail pollen extract and preparation process and use thereof - Google Patents
Cattail pollen extract and preparation process and use thereof Download PDFInfo
- Publication number
- CN1188406C CN1188406C CNB031155081A CN03115508A CN1188406C CN 1188406 C CN1188406 C CN 1188406C CN B031155081 A CNB031155081 A CN B031155081A CN 03115508 A CN03115508 A CN 03115508A CN 1188406 C CN1188406 C CN 1188406C
- Authority
- CN
- China
- Prior art keywords
- extract
- puhuang
- cattail pollen
- pollen extract
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000000605 extraction Methods 0.000 title claims description 5
- 244000134857 Typha capensis Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 230000002107 myocardial effect Effects 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 18
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 12
- 229930003935 flavonoid Natural products 0.000 claims abstract description 11
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 11
- 239000011347 resin Substances 0.000 claims abstract description 9
- 229920005989 resin Polymers 0.000 claims abstract description 9
- 230000000302 ischemic effect Effects 0.000 claims abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims 1
- 238000012869 ethanol precipitation Methods 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 12
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 12
- 230000036284 oxygen consumption Effects 0.000 abstract description 12
- 241000233948 Typha Species 0.000 abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 abstract description 10
- 239000001301 oxygen Substances 0.000 abstract description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 206010061216 Infarction Diseases 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000007574 infarction Effects 0.000 abstract description 6
- 235000014655 lactic acid Nutrition 0.000 abstract description 4
- 239000004310 lactic acid Substances 0.000 abstract description 4
- 102000004420 Creatine Kinase Human genes 0.000 abstract description 3
- 108010042126 Creatine kinase Proteins 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 238000005377 adsorption chromatography Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 230000008859 change Effects 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 241000282465 Canis Species 0.000 description 12
- 241000229143 Hippophae Species 0.000 description 7
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 7
- 240000001398 Typha domingensis Species 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 6
- 244000132619 red sage Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- FMEHGPQTMOPUGM-UHFFFAOYSA-N 3,3'-dimethylquercetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC)=C1 FMEHGPQTMOPUGM-UHFFFAOYSA-N 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010077078 Creatinase Proteins 0.000 description 2
- QHLKSZBFIJJREC-SPSUIZEHSA-N Isorhamnetin-3-O-nehesperidine Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=C1 QHLKSZBFIJJREC-SPSUIZEHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 235000000864 Typha angustata Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 229940000032 cardiovascular system drug Drugs 0.000 description 2
- 210000003748 coronary sinus Anatomy 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- OIZKUGTZYXEXES-UHFFFAOYSA-N isorhamnetin 3-O-rungioside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(O)C(CO)O2)O)=C1 OIZKUGTZYXEXES-UHFFFAOYSA-N 0.000 description 2
- QHLKSZBFIJJREC-LRVFLTSZSA-N isorhamnetin-3-O-neohesperidoside Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O[C@H]1OC1=C(c2cc(OC)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QHLKSZBFIJJREC-LRVFLTSZSA-N 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HDBLGMREZKSBMK-UHFFFAOYSA-N tamarixetin 3-O-neohesperidoside Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 HDBLGMREZKSBMK-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- -1 C 5 alcohols Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 235000004224 Typha angustifolia Nutrition 0.000 description 1
- 240000000260 Typha latifolia Species 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- CQLRUIIRRZYHHS-UVHBULKNSA-N isorhamnetin 3-O-beta-D-galactopyranoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)=C1 CQLRUIIRRZYHHS-UVHBULKNSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域:Technical field:
本发明涉及医药技术领域,是蒲黄提取物及其制备方法和将蒲黄提取物用于制备防治心肌缺血性心血管疾病药物或食品的用途。The invention relates to the technical field of medicine, and relates to an extract of Puhuang and a preparation method thereof and the use of the extract of Puhuang in preparing medicine or food for preventing and treating myocardial ischemic cardiovascular disease.
背景技术:Background technique:
蒲黄为常用药材,来源于香蒲科Typhaceae香蒲属Typha L.水烛香蒲Typhaangustifolia L.、长苞香蒲Typha angustata Bory et Chaub、宽叶香蒲T.latifolia L.等多种植物的花粉。别名蒲棒花粉、蒲草黄等。其药用历史悠久,汉代《神农本草经》列为上品。具有止血、化瘀、通淋的功效。用于吐血,衄血,咯血,崩漏,外伤出血,闭经通经,脘腹刺痛,跌扑肿痛,血淋涩痛。《本草纲目》记载:“蒲黄手足厥阴血分药也,故能治血止痛,生则能行,熟则能止,与五灵脂同用,能治一切心腹诸痛”。祖国医学描述的“胸脾”,“真心痛”,其证候与冠心病心绞痛相似,据临床报道,由蒲黄和五灵脂为主组成的“失笑散”加味对冠心病有一定疗效,此外,近年来研究发现单味蒲黄具有改善微循环,防治家兔实验性动脉粥样硬化(AS),有降低血脂和减轻AS斑块的作用,并可降低高脂血症患者的血清胆固醇水平,降低血小板粘附率和聚集率及改善冠心病的临床症状等作用,且毒副作用少,使用安全。蒲黄主要含有甾类、黄酮类、长链脂肪烃类化合物、氨基酸类、无机成分等(1、植物学报,1990,32(2):137;2、中国药学杂志,1998,33(10):587;3、Thrombosis Research,1990,57(6):957;4、中草药,1998,27(11):693)。至今未见有关用蒲黄提取物防治心肌缺血性心血管疾病的报道。Cattail is a commonly used medicinal material, derived from the pollen of various plants such as Typha L. Typha angustifolia L., Typha angustata Bory et Chaub, Typha angustata Bory et Chaub and T. latifolia L. of the family Typhaceae. Alias cattail pollen, cattail yellow and so on. Its medicinal use has a long history, and was listed as top grade in "Shen Nong's Materia Medica" in the Han Dynasty. It has the effects of stopping bleeding, removing blood stasis and treating stranguria. For vomiting blood, epistaxis, hemoptysis, uterine bleeding, traumatic hemorrhage, amenorrhea and dredging menstruation, epigastric pain, tumbling and swelling pain, bloody stranguria and astringent pain. "Compendium of Materia Medica" records: "Puhuang's hands and feet Jueyin blood is also divided into medicines, so it can cure blood and relieve pain. It can work when it is raw, and it can stop when it is cooked. When used together with Wulingzhi, it can cure all kinds of pain in the heart." The syndromes of "chest and spleen" and "true pain" described in traditional Chinese medicine are similar to coronary heart disease angina pectoris. According to clinical reports, the flavored "Shixiaosan" mainly composed of Puhuang and Wulingzhi has a certain curative effect on coronary heart disease. In addition, in recent years, studies have found that single herb Puhuang can improve microcirculation, prevent experimental atherosclerosis (AS) in rabbits, reduce blood lipids and reduce AS plaques, and can reduce serum cholesterol in patients with hyperlipidemia. Level, reduce the platelet adhesion rate and aggregation rate and improve the clinical symptoms of coronary heart disease, and less toxic side effects, safe to use. Puhuang mainly contains steroids, flavonoids, long-chain aliphatic hydrocarbons, amino acids, inorganic components, etc. : 587; 3. Thrombosis Research, 1990, 57(6): 957; 4. Chinese herbal medicine, 1998, 27(11): 693). So far, there is no report about the prevention and treatment of myocardial ischemic cardiovascular disease with Puhuang extract.
发明内容:Invention content:
本发明提供一种蒲黄提取物及其制备方法。The invention provides an extract of Pollen Pollen and a preparation method thereof.
本发明制备方法如下:The preparation method of the present invention is as follows:
蒲黄用含水乙醇加热提取后,将提取液浓缩,浓缩液离心或过滤,取离心上清液或滤液;将离心上清液或滤液用大孔树脂吸附,先用水淋洗除去杂质,再用含水低级醇洗脱;低级醇洗脱液浓缩至一定体积,用乙醇醇沉,先除去沉淀,再浓缩至干或除去乙醇后喷雾干燥,得蒲黄提取物。After heat-extracting Puhuang with water-containing ethanol, concentrate the extract, centrifuge or filter the concentrate, and take the centrifuged supernatant or filtrate; absorb the centrifuged supernatant or filtrate with macroporous resin, rinse with water to remove impurities, and then use Elute with water-containing lower alcohol; concentrate the eluent of lower alcohol to a certain volume, precipitate with ethanol, first remove the precipitate, then concentrate to dryness or remove ethanol and then spray dry to obtain the extract of Puhuang.
[蒲黄提取物化学成分的分析][Analysis of Chemical Components of Puhuang Extract]
蒲黄提取物通过硅胶、sephadexLH-20、ODS等反相色谱担体柱色谱获得5个化合物:1、槲皮素-3,3′-二甲醚;2、槲皮素-3,3′-二甲醚-4′-O-β-D-吡喃葡萄糖苷;3、异鼠李素-3-O-β-D-丰乳糖苷;4、异鼠李素-3-O-新橙皮糖苷;5、香蒲新苷。经化学、波谱方法测定,前三个化合物的化学结构通式如下:Five compounds were obtained from the extract of Puhuang through silica gel, sephadexLH-20, ODS and other reversed-phase chromatography supports: 1. Quercetin-3,3′-dimethyl ether; 2. Quercetin-3,3′- Dimethyl ether-4'-O-β-D-glucopyranoside; 3. Isorhamnetin-3-O-β-D-galactopyranoside; 4. Isorhamnetin-3-O-new orange glucoside; 5, Typha new glycosides. Determined by chemical and spectral methods, the general chemical structure formulas of the first three compounds are as follows:
其中:in:
当R1=CH3,R2=H,R3=CH3时,其为槲皮素-3,3′-二甲醚;When R 1 =CH 3 , R 2 =H, R 3 =CH 3 , it is quercetin-3,3'-dimethyl ether;
当R1=CH3,R2=Glu(葡萄糖),R3=CH3时,其为槲皮素-3,3′-二甲醚-4′-O-β--D-吡喃葡萄糖苷When R 1 =CH 3 , R 2 =Glu (glucose), R 3 =CH 3 , it is quercetin-3,3'-dimethyl ether-4'-O-β--D-glucopyranose Glycoside
当R1=Gala(半乳糖),R2=H,R3=CH3时,其为异鼠李素-3-O-β-D-半乳糖苷When R 1 =Gala (galactose), R 2 =H, R 3 =CH 3 , it is isorhamnetin-3-O-β-D-galactoside
其余2个化合物的化学结构式为:The chemical structural formulas of the remaining 2 compounds are:
异鼠李素-3-O-新橙皮糖苷 香蒲新苷Isorhamnetin-3-O-neohesperidoside Typhaloside
由此可见,蒲黄提取物是黄酮类成分的混合物。用HPLC定量分析表明,其主要含有异鼠李素-3-O-β-D-半乳糖苷、异鼠李素-3-O-新橙皮糖苷、香蒲新苷,三者的含量占总提取物的40%以上。用紫外分光光度法测定,总黄酮含量占总提取物的50%以上。经动物实验,蒲黄提取物能有效防治心肌缺血性心血管疾病。It can be seen that the extract of Puhuang is a mixture of flavonoids. Quantitative analysis by HPLC shows that it mainly contains isorhamnetin-3-O-β-D-galactoside, isorhamnetin-3-O-neohesperidoside, and cattail glycoside, and the content of the three accounts for the total More than 40% of the extract. Determined by ultraviolet spectrophotometry, the total flavonoid content accounts for more than 50% of the total extract. According to animal experiments, Puhuang extract can effectively prevent and treat myocardial ischemic cardiovascular disease.
附图说明:Description of drawings:
图1为蒲黄提取物对犬冠脉结扎心外膜电图ST段总和(∑ST)影响的曲线图Figure 1 is a graph showing the effect of Puhuang extract on the sum of the ST segments (∑ST) of the epicardial electrogram in dogs with coronary artery ligation
图2为蒲黄提取物对犬冠脉结扎心肌梗塞范围(N-ST)影响的曲线图Figure 2 is a graph showing the effect of Puhuang extract on the range of myocardial infarction (N-ST) in dogs with coronary artery ligation
图3为蒲黄提取物对犬心肌耗氧量(ml/min.100g-1)影响的曲线图Figure 3 is a graph showing the effect of Puhuang extract on the oxygen consumption (ml/min.100g -1 ) of canine myocardium
图4为蒲黄提取物对犬心肌氧摄取率(%)影响的曲线图Fig. 4 is the curve graph of the effect of Puhuang extract on the oxygen uptake rate (%) of canine myocardium
图5为蒲黄提取物对犬冠脉流量(ml/min)影响的曲线图Figure 5 is a graph showing the effect of Puhuang extract on canine coronary flow (ml/min)
具体实施方式:Detailed ways:
蒲黄提取物的制备:将蒲黄用40~95%乙醇热提2次,每次溶媒用量约为生药量的4~12倍;合并提取液后浓缩,浓缩液离心或过滤;将上清液或过滤液通过大孔树脂吸附,大孔树脂为以苯乙烯为架桥材料的聚苯乙烯型多孔性吸附树脂,如D101、D201、ZTC-1、AB-8、1300-1型大孔树脂等,先用水淋洗除去杂质;再用含水低级醇洗脱,低级醇为甲醇、乙醇或丙醇等C1~C5的醇类,浓度为40~95%,用量为生药量的5~15倍;收集低级醇洗脱液,浓缩后用乙醇醇沉,使乙醇终浓度为70~95%;醇沉后的上清液浓缩至干,得本发明的蒲黄提取物,干燥粉碎后备用,成品收率为生药量的1.0%以上。Preparation of Puhuang extract: Thermally extract Puhuang with 40-95% ethanol twice, and the amount of solvent used each time is about 4-12 times the amount of crude drug; the combined extracts are concentrated, and the concentrated solution is centrifuged or filtered; the supernatant The liquid or filtrate is adsorbed by the macroporous resin, which is a polystyrene-type porous adsorption resin with styrene as a bridging material, such as D101, D201, ZTC-1, AB-8, 1300-1 macroporous Resins, etc., first wash with water to remove impurities; then elute with water-containing lower alcohols, the lower alcohols are C 1 ~ C 5 alcohols such as methanol, ethanol or propanol, the concentration is 40 ~ 95%, and the dosage is 5% of the crude drug amount. ~15 times; collect the lower alcohol eluate, concentrate and precipitate with ethanol, so that the final concentration of ethanol is 70-95%; the supernatant after alcohol precipitation is concentrated to dryness, and the Pollen extract of the present invention is obtained, which is dried and pulverized It is used for later use, and the yield of the finished product is more than 1.0% of the crude drug amount.
实施例1Example 1
100公斤蒲黄药材,投入提取罐,以100升70%乙醇常温浸泡24小时,在90~100℃依次用70%乙醇800升煮提3次,每次提取时间为2小时,合并3次提取液,浓缩至50升,过滤,将滤液用蒸馏水调节至100升。再缓缓通过装有200升ZTC-1型大孔树脂(天津正天成澄清技术有限公司生产)的吸附柱,用1000升蒸馏水淋洗除去杂质;再用1000升70%乙醇洗脱,收集洗脱液,浓缩至10升,在搅拌下缓缓加入100升95%乙醇,加毕,静置12小时,离心弃沉淀,上清液浓缩至干,进一步干燥并粉碎,得黄色粉末状的蒲黄提取物1.8公斤,按生药量计得率为1.8%。Put 100 kg of Puhuang medicinal materials into the extraction tank, soak in 100 liters of 70% ethanol at room temperature for 24 hours, boil and extract 3 times with 800 liters of 70% ethanol at 90-100 ° C, each extraction time is 2 hours, and combine the 3 extractions liquid, concentrated to 50 liters, filtered, and the filtrate was adjusted to 100 liters with distilled water. Slowly pass through the adsorption column that 200 liters of ZTC-1 type macroporous resin (produced by Tianjin Zhengtiancheng Clarification Technology Co., Ltd.) is housed again, remove impurity with 1000 liters of distilled water rinses; Remove liquid, concentrate to 10 liters, slowly add 100 liters of 95% ethanol under stirring, after adding, let it stand for 12 hours, centrifuge to discard the precipitate, concentrate the supernatant to dryness, further dry and pulverize to obtain yellow powder The yellow extract is 1.8 kg, and the yield is 1.8% based on crude drug amount.
生物活性测定Bioactivity assay
采用麻醉犬心肌梗塞模型,观察本发明蒲黄提取物对急性心肌梗塞模型的治疗作用及心肌耗氧量的影响。具体实验方法如下:An anesthetized canine myocardial infarction model was used to observe the therapeutic effect of the Puhuang extract of the present invention on the acute myocardial infarction model and the influence of myocardial oxygen consumption. The specific experimental method is as follows:
一、蒲黄提取物对麻醉犬冠状动脉结扎造成急性心肌梗塞模型的治疗作用1. Therapeutic effect of Puhuang extract on the model of acute myocardial infarction caused by coronary artery ligation in anesthetized dogs
1材料与方法1 Materials and methods
1.1动物1.1 Animals
健康杂种犬,由第二军医大学动物中心提供,动物饲养合格证号:军医动字第D2001-31号。雄雌兼用。体重10~14kg。18条犬随机分为3组,每组6条。Healthy mongrel dogs were provided by the Animal Center of the Second Military Medical University. Both male and female. Weight 10-14kg. 18 dogs were randomly divided into 3 groups, 6 dogs in each group.
1.2剂量设置 分组与剂量见表1,1.2 Dose setting Grouping and dosage are shown in Table 1.
表1 实验分组及给药方案 Table 1 Experimental grouping and dosing regimen
组别 给药途径 剂量 动物数(条)Groups Route of Administration Dose Number of Animals (Pieces)
生理盐水对照组 口服,单次给药 1ml/kg 6Normal saline control group Orally, single administration 1ml/kg 6
丹参片组 口服,单次给药 1片/kg 6Danshen tablet group Oral administration,
蒲黄提取物组 口服,单次给药 8mg/kg 6Puhuang extract group Oral administration, single administration 8mg/kg 6
1.3方法1.3 Method
犬急性心肌缺血模型复制及心外膜电图的测定参照药理实验的方法学[徐叔云等主编.药理实验方法学(第三版).第八篇:心血管系统药物实验法。北京:人民卫生出版社,2002:1054]。在模型犬心脏表面放置“多点固定式”心外膜电极并固定,标测30个点的心外膜电极。信号通过PowerLab数据记录分析系统(ML785/8S,AD Instruments,澳大利亚)连接到实时记录计算机上,计算规定的不同时间点心外膜电图ST段升高的导联数和ST段升高值的总和,藉以了解心肌缺血的程度与范围。Canine acute myocardial ischemia model replication and epicardial electrogram measurement refer to the methodology of pharmacological experiments [Edited by Xu Shuyun et al. Pharmacological Experimental Methodology (Third Edition). Eighth: Cardiovascular System Drug Experimental Method. Beijing: People's Medical Publishing House, 2002: 1054]. "Multi-point fixed" epicardial electrodes were placed on the surface of the dog model heart and fixed, and the epicardial electrodes at 30 points were mapped. The signal was connected to the real-time recording computer through the PowerLab data recording and analysis system (ML785/8S, AD Instruments, Australia), and the total number of leads and the ST segment elevation value of the epicardial electrogram at different times were calculated. , in order to understand the degree and scope of myocardial ischemia.
结扎3小时后取心脏称重,染色,梗死区不着色,非梗死区着黑色,剪去着色部分,将未着色的梗死区称重。冠脉结扎前及给药后3小时各从右心室取血3ml,取血清测肌酸肌酶CK及乳酸LDH。Three hours after ligation, the heart was weighed and stained. The infarcted area was not colored, and the non-infarcted area was colored black. The colored part was cut off, and the uncolored infarcted area was weighed. Before coronary artery ligation and 3 hours after administration, 3ml of blood was collected from the right ventricle, and serum was taken to measure creatine, creatinase, CK and lactate LDH.
试验结果以 x±S表示,用SPSS统计软件进行方差分析,比较各组间相差的显著性。The test results are based on x ± S means, using SPSS statistical software for analysis of variance, comparing the significance of the difference between the groups.
2结果2 results
2.1对心肌缺血程度(心外膜电图∑ST)的影响结果见表2和图12.1 The results of the effect on the degree of myocardial ischemia (epicardial electrogram ∑ST) are shown in Table 2 and Figure 1
表2蒲黄提取物对犬冠脉结扎心外膜电图ST段总和(∑ST)的影响
(mV, x±s,n=6只/组)(mV, x±s, n=6/group)
给药后After administration
组 给药group administration
剂量 指标Dosage Index
别 前 15min 30min 60min 90min 120min 180minBefore 15min 30min 60min 90min 120min 180min
生 1 x±s 220.3 238.3± 269.0± 289.3± 301.2± 274.7± 259.0±Birth 1 x±s 220.3 238.3± 269.0± 289.3± 301.2± 274.7± 259.0±
理 ml/kg ±65.7 54.2 44.1 49.4 49.5 84.2 67.5Rationale ml/kg ±65.7 54.2 44.1 49.4 49.5 84.2 67.5
盐Salt
水water
变化% 10.5±10.1 27.4±24.4 36.0±19.5 43.7±31.5 26.2±21.3 19.9±19.1% Change 10.5±10.1 27.4±24.4 36.0±19.5 43.7±31.5 26.2±21.3 19.9±19.1
丹 1片
x±s 221.8 176.8± 146.0± 222.7±90.2 242.8± 242.7± 227.8±
参 /kg ±61.1 64.5 39.5*** 110.1 122.4 106.0Reference /kg ±61.1 64.5 39.5 *** 110.1 122.4 106.0
片piece
变化% -22.2± -33.5± -1.9± 7.6±30.0 5.7±30.6 0.2±26.5% Change -22.2± -33.5± -1.9± 7.6±30.0 5.7±30.6 0.2±26.5
9.2*** 8.6*** 20.2*** 9.2 *** 8.6 *** 20.2 ***
蒲 8mg/k x±s 207.8 137.2± 140.4± 148.8± 149.8± 143.0±39.8 144.4±36.7Po 8mg/k x±s 207.8 137.2± 140.4± 148.8± 149.8± 143.0±39.8 144.4±36.7
黄 g ±29.5 66.2 46.4*** 37.9** 28.9** Yellow g ±29.5 66.2 46.4 *** 37.9 ** 28.9 **
变化% -35.4± -33.7± -29.1± -27.6± -30.4± -28.9±% Change -35.4± -33.7± -29.1± -27.6± -30.4± 8.9
24.5*** 13.8*** 11.1*** 12.4*** 19.6*** 20.7*** 24.5 *** 13.8 *** 11.1 *** 12.4 *** 19.6 *** 20.7 ***
**P<0.05,***P<0.01与生理盐水组比较 ** P<0.05, *** P<0.01 compared with normal saline group
由表2和图1看出,冠脉结扎后15分钟,生理盐水对照组心外电图ST段总和(∑ST)明显升高,至90分钟(min)时∑ST升高达301.2±49.5,此后缓慢回落;蒲黄提取物组8mg/kg灌胃给药后能减轻心肌缺血程度,∑ST显著下降,作用从给药15分钟持续至180分钟,各时间点与生理盐水组比较均有显著差异(P<0.01)。阳性对照丹参片组在给药后15分钟至60分钟,∑ST下降,与生理盐水组同时间点比较差异显著(P<0.01),但60分钟后至180分钟与生理盐水组无显著性差异。It can be seen from Table 2 and Figure 1 that 15 minutes after coronary artery ligation, the sum of the ST segments (∑ST) of the electrocardiogram in the normal saline control group increased significantly, and the ∑ST increased to 301.2±49.5 at 90 minutes (min), and thereafter slow down; Puhuang extract group can reduce the degree of myocardial ischemia after 8mg/kg intragastric administration, ΣST decreased significantly, and the effect lasted from 15 minutes to 180 minutes after administration, and there were significant differences at each time point compared with the normal saline group Difference (P<0.01). In the positive control Danshen Tablets group, ΣST decreased from 15 minutes to 60 minutes after administration, which was significantly different from that of the normal saline group at the same time point (P<0.01), but there was no significant difference from the normal saline group after 60 minutes to 180 minutes .
2.2对心肌缺血范围(心外膜电图N-ST)的影响,结果见表3和图22.2 The effect on the extent of myocardial ischemia (N-ST epicardial electrogram), the results are shown in Table 3 and Figure 2
表3蒲黄提取物对犬冠脉结扎心肌梗塞范围(N-ST)的影响 Table 3 The effect of Puhuang extract on the size of myocardial infarction (N-ST) in dogs with coronary artery ligation
(点数, x±s,n=6只/组)(Points, x±s, n=6/group)
给药后组 给药
剂量 指标别 前 15min 30min 60min 90min 120min 180min生 1 x±s 27.3± 28.0±1.8 29.2±1.0 29.7±0.5 29.5±0.8 27.8±2.4 26.8±2.7理 ml/kg 1.8盐 变化% 2.5±3.0 7.0±6.2 8.9±7.0 8.2±5.3 1.8±4.4 -1.9±6.0水丹 1 x±s 28.0± 24.7±4.5 22.8± 23.8±4.7** 25.8±4.7 25.3±4.1 24.5±3.8参 片/kg 1.7 2.9**片 变化% -12.0±13.7 -18.5± -15.0± -7.5±17.6 -9.3±15.3 -12.5±12.415min before dose index 30min 60min 90min 120min 180min 1 x±s 27.3± 28.0±1.8 29.2±1.0 29.7±0.5 29.5±0.8 27.8±2.4 26.8±2.7 theoretical ml/kg 1.8 Salt change% 2.5±3.0 7.0±6.2 8.9 ±7.0 8.2±5.3 1.8±4.4 -1.9±6.0 Shuidan 1 x±s 28.0± 24.7±4.5 22.8± 23.8±4.7 ** 25.8±4.7 25.3±4.1 24.5±3.8 Tablets/kg 1.7 2.9 ** Table change% -12.0±13.7 -18.5± -15.0± -7.5±17.6 -9.3±15.3 -12.5±12.4
8.6*** 15.8***蒲 8mg/ x±s 28.0± 24.0±4.9 22.8± 22.7± 23.5±3.2**22.5±4.7 22.8±5.0黄 kg 1.4 4.1*** 3.6*** 8.6 *** 15.8 *** Po 8mg/ x±s 28.0± 24.0±4.9 22.8± 22.7± 23.5±3.2 ** 22.5±4.7 22.8±5.0 yellow kg 1.4 4.1 *** 3.6 ***
变化% -14.7±14.4 -18.7± -19.2± -16.1± -19.6± -18.4±18.2% Change -14.7±14.4 -18.7± -19.2± -16.1± -12.4±18.
12.1*** 10.6*** 10.2*** 17.3** 12.1 *** 10.6 *** 10.2 *** 17.3 **
**P<0.05,***P<0.01与生理盐水组同时间点的改变值比较 ** P<0.05, *** P<0.01 Compared with the change value of the normal saline group at the same time point
由表3和图2看出,蒲黄提取物8mg/kg能显著缩小心肌缺血范围(P<0.01),降低N-ST值,作用可持续120分钟。阳性对照药丹参片在给药后30分钟-60分钟心肌缺血范围与生理盐水组同时间点比较非常显著下降(P<0.01),但从90分钟起与生理盐水组无显著性差异,起效快而作用时间短。It can be seen from Table 3 and Figure 2 that 8 mg/kg of Puhuang extract can significantly reduce the extent of myocardial ischemia (P<0.01), lower the N-ST value, and the effect can last for 120 minutes. The range of myocardial ischemia in the positive control drug Danshen Tablets was significantly decreased compared with the normal saline group at the same time point from 30 minutes to 60 minutes after administration (P<0.01), but there was no significant difference from the normal saline group from 90 minutes onwards. Fast and short duration of action.
2.3对心肌梗塞范围影响的定量组织学检测,结果见表42.3 Quantitative histological detection of the influence on the range of myocardial infarction, the results are shown in Table 4
表4蒲黄提取物对N-BT染色测定心肌梗塞范围的影响 Table 4 Effect of Puhuang Extract on N-BT Staining Determination of Myocardial Infarction Range
( x±s,n=6只/组)( x±s, n=6/group)
组别 剂量 梗塞区/全心(%) 梗塞区/左心室(%)Group Dose Infarct area/whole heart (%) Infarct area/left ventricle (%)
生理盐水 1ml/kg 12.10±2.28 23.24±1.97Normal saline 1ml/kg 12.10±2.28 23.24±1.97
丹参片 1片/kg 9.29±0.96** 17.16±3.24***
蒲黄提取物 8mg/kg 9.71±1.02** 18.69±1.59** Pollen Extract 8mg/kg 9.71±1.02 ** 18.69±1.59 **
**P<0.05,***P<0.01与生理盐水组比较 ** P<0.05, *** P<0.01 compared with normal saline group
由表4看出,蒲黄提取物8mg/kg灌胃给药能显著减少心肌梗塞范围。蒲黄提取物梗塞区/全心的比值和梗塞区/左心室的比值与生理盐水组比较下降非常显著(P<0.01)。阳性对照组、蒲黄提取物组均能显著地缩小心肌梗塞范围(P<0.01)。It can be seen from Table 4 that oral administration of Puhuang extract at 8 mg/kg can significantly reduce the extent of myocardial infarction. The ratio of infarct area/whole heart and infarct area/left ventricle of Puhuang extract decreased significantly compared with the normal saline group (P<0.01). Both the positive control group and the Puhuang extract group could significantly reduce the size of myocardial infarction (P<0.01).
2.4蒲黄提取物对冠脉结扎后血清生化指标的影响,结果见表52.4 The effect of Puhuang extract on serum biochemical indicators after coronary artery ligation, the results are shown in Table 5
表5蒲黄提取物对冠脉结扎犬右心室血清生化指标的影响 Table 5 Effect of Puhuang Extract on Serum Biochemical Indexes of Right Ventricle in Dogs with Coronary Artery Ligation
( x±s,n=6只/组)( x±s, n=6/group)
项目 时间 生理盐水1ml/kg 丹参片1片/kg 蒲黄提取物8mg/kgItem Time Physiological Saline 1ml/
CK(U/I) 给药前 149.76±15.14 149.76±20.95 125.47±11.16CK(U/I) Before administration 149.76±15.14 149.76±20.95 125.47±11.16
给药后 615.22±45.51ΔΔΔ 392.5 1±57.73***ΔΔΔ 442.53±50.85***ΔΔΔ After administration 615.22±45.51 ΔΔΔ 392.5 1±57.73 ***ΔΔΔ 442.53±50.85 ***ΔΔΔ
LDH 给药前 367.98±68.45 404.39±47.48 436.85±98.37LDH before administration 367.98±68.45 404.39±47.48 436.85±98.37
(IU/L) 给药后 959.21±109.21ΔΔΔ 776.67±68.13***ΔΔΔ 807.46±132.87**ΔΔΔ (IU/L) After administration 959.21±109.21 ΔΔΔ 776.67±68.13 ***ΔΔΔ 807.46±132.87 **ΔΔΔ
**P<0.05,***P<0.01与生理盐水组比较;ΔΔP<0.05,ΔΔΔP<0.01与给药前比较 ** P<0.05, *** P<0.01 compared with normal saline group; ΔΔ P<0.05, ΔΔΔ P<0.01 compared with before administration
由表5看出,冠状动脉结扎后各组血清肌酸肌酶CK及乳酸LDH均升高。蒲黄提取物8mg/kg及阳性对照药丹参片均能非常显著的降低血清肌酸激酶的升高程度(P<0.01);蒲黄提取物及阳性对照药还能显著降低右心室动脉血血清乳酸的升高程度(P<0.01)。It can be seen from Table 5 that serum creatine creatinase CK and lactate LDH in each group increased after coronary artery ligation. Puhuang extract 8mg/kg and the positive control drug Danshen Tablets can both significantly reduce the elevation of serum creatine kinase (P<0.01); Puhuang extract and the positive control drug can also significantly reduce the serum level of right ventricular arterial blood Increased degree of lactic acid (P<0.01).
实验结果表明,蒲黄提取物灌胃给药能显著降低冠脉结扎犬的心肌缺血的程度,缩小心肌缺血范围,定量组织学检测与心外膜电图测定的结果一致,与生理盐水对照组比较,梗塞区显著缩小,证明蒲黄提取物灌胃给药对犬冠状动脉结扎引起的急性心肌梗塞有明显的治疗作用,实验结果还表明,蒲黄提取物能显著降低犬冠脉结扎后血清乳酸、肌酸激酶升高的程度,提示其可减少急性缺血心肌细胞CK、乳酸的溢出,减轻心肌缺血时的细胞损害,对心肌细胞有保护作用。The experimental results show that oral administration of Puhuang extract can significantly reduce the degree of myocardial ischemia in dogs with coronary artery ligation, and narrow the scope of myocardial ischemia. Compared with the control group, the infarction area was significantly reduced, which proves that oral administration of Puhuang extract has a significant therapeutic effect on acute myocardial infarction caused by canine coronary artery ligation. The experimental results also show that Puhuang extract can significantly reduce the incidence of coronary artery ligation The elevated levels of serum lactic acid and creatine kinase suggest that it can reduce the overflow of CK and lactic acid in acute ischemic cardiomyocytes, reduce cell damage during myocardial ischemia, and have a protective effect on cardiomyocytes.
二、蒲黄提取物对麻醉犬心肌耗氧量的影响2. Effect of Puhuang Extract on Myocardial Oxygen Consumption in Anesthetized Dogs
1材料与方法1 Materials and methods
1.1动物1.1 Animals
健康杂种犬,由第二军医大学动物中心提供,动物饲养合格证号:军医动字第D2001-31号。雄雌兼用。11~13kg。15条,随机分为3组,每组5条。Healthy mongrel dogs were provided by the Animal Center of the Second Military Medical University. Both male and female. 11~13kg. 15 pieces were randomly divided into 3 groups, 5 pieces in each group.
1.2剂量设置见表61.2 See Table 6 for dose settings
表6各组剂量设置表
组别 给药途径 剂量 动物数(条)Groups Route of Administration Dose Number of Animals (Pieces)
生理盐水对照组 口服,单次给药 1ml/kg 5Normal saline control group Orally, single administration 1ml/
沙棘总黄酮组 口服,单次给药 24mg/kg 5Seabuckthorn total flavonoids group Oral, single administration 24mg/
蒲黄提取物组 口服,单次给药 8mg/kg 5Puhuang extract group Oral administration, single dose 8mg/
1.3试验方法1.3 Test method
参照徐叔云的方法(徐叔云等,主编.药理实验方法学(第三版).第八篇:心血管系统药物实验法。北京:人民卫生出版社,2002:1054)。麻醉犬,分离右侧股动脉,备动脉血气分析。暴露心脏,做成心包床,游离升主动脉根部和左冠状动脉前降支上部,分别放置适宜内径的电磁流量计探头(MFV-1100/1200型,日本Nihon Kohden公司)测冠脉流量。分离右侧颈静脉,引导心导管插入冠状静脉窦,心导管。同步抽取冠状窦及股动脉血标本(0.5%肝素抗凝),用血气分析仪(DH-1830型血气酸硷分析仪,南京分析仪器厂)测定pO2,pH,换算成动脉和静脉血氧含量。实验结束时将心脏称重,并以10-15ml10%上海高级碳素墨水逆流灌注于电磁流量计测量部位以下区域,切下染黑区并称重,用于计算心肌耗氧量。公式为:心肌耗氧量(ml/min/100g)=冠脉血流量ml/min/100g×(动脉血氧ml%-冠状窦血氧ml%)。Refer to Xu Shuyun's method (Xu Shuyun et al., editor-in-chief. Pharmacological Experimental Methodology (Third Edition). Chapter 8: Cardiovascular System Drug Experimental Method. Beijing: People's Medical Publishing House, 2002: 1054). The dog was anesthetized, the right femoral artery was isolated, and arterial blood gas analysis was prepared. Expose the heart, make a pericardial bed, free the root of the ascending aorta and the upper part of the left anterior descending coronary artery, and place electromagnetic flowmeter probes (MFV-1100/1200, Nihon Kohden, Japan) with appropriate inner diameters to measure coronary flow. The right jugular vein was separated, and the cardiac catheter was inserted into the coronary sinus, cardiac catheterization. Simultaneously extract coronary sinus and femoral artery blood samples (0.5% heparin anticoagulant), measure pO 2 and pH with a blood gas analyzer (DH-1830 blood gas acid-base analyzer, Nanjing Analytical Instrument Factory), and convert them into arterial and venous blood oxygen content. At the end of the experiment, the heart was weighed, and 10-15ml of 10% Shanghai advanced carbon ink was perfused countercurrently in the area below the measurement site of the electromagnetic flowmeter, and the black stained area was cut off and weighed to calculate the myocardial oxygen consumption. The formula is: myocardial oxygen consumption (ml/min/100g)=coronary blood flow ml/min/100g×(arterial blood oxygen ml%-coronary sinus blood oxygen ml%).
实验数据以 x±s表示,用SPSS 10.0软件进行方差分析,作显著性检验。Experimental data with x ± s means, using SPSS 10.0 software for analysis of variance, for significance testing.
2结果2 results
蒲黄提取物对犬心肌耗氧量的影响见表7和图3See Table 7 and Figure 3 for the effect of Puhuang extract on the oxygen consumption of canine myocardium
表7蒲黄提取物对犬心肌耗氧量(mL/min.100g-1)的影响( x±s,n=5)Table 7 Effect of Puhuang extract on canine myocardial oxygen consumption (mL/min.100g -1 ) (x±s, n=5)
给 药 后After giving medicine
组别 指标 给药前Group Index Index Before administration
30min 60min 90min 120min|
生理盐水 x±S 204.6±9.3 210.1±9.4 205.2±5.4 205.2±5.5 212.8±4.8Normal saline x±S 204.6±9.3 210.1±9.4 205.2±5.4 205.2±5.5 212.8±4.8
1ml/kg 变化% 2.8±5.5 0.4±4.2 0.4±3.1 4.2±4.91ml/kg Change % 2.8±5.5 0.4±4.2 0.4±3.1 4.2±4.9
沙棘总黄酮 x±S 213.7±5.8 191.5±10.7ΔΔΔ 186.4±9.4ΔΔΔ 188.2±9.4ΔΔΔ 189.9±8.5ΔΔ Sea buckthorn total flavonoids x±S 213.7±5.8 191.5±10.7 ΔΔΔ 186.4±9.4 ΔΔΔ 188.2±9.4 ΔΔΔ 189.9±8.5 ΔΔ
24mg/kg 变化% -10.4±4.4*** -12.7±3.8*** -12.0±2.2*** -11.1±3.6*** 24mg/kg Change % -10.4±4.4 *** -12.7±3.8 *** -12.0±2.2 *** -11.1±3.6 ***
蒲黄提取物 x±S 214.0±10.0 183.7±12.2ΔΔ 179.3±9.1ΔΔΔ 182.7±12.3ΔΔ 191.5±14.0Pollen extract x±S 214.0±10.0 183.7±12.2 ΔΔ 179.3±9.1 ΔΔΔ 182.7±12.3 ΔΔ 191.5±14.0
8mg/kg 变化% -14.2±3.1*** -16.1±4.9*** -14.4±8.3*** -10.3±7.7*** 8mg/kg Change % -14.2±3.1 *** -16.1±4.9 *** -14.4±8.3 *** -10.3±7.7 ***
ΔΔP<0.05,ΔΔΔP<0.01与给药前比较;**P<0.05,***P<0.01与生理盐水组比较 ΔΔ P<0.05, ΔΔΔ P<0.01 compared with before administration; ** P<0.05, *** P<0.01 compared with normal saline group
从表7、图3可以看出,蒲黄提取物8mg/kg灌胃后心肌耗氧量同生理盐水组相比有所下降,从30分钟开始至120分钟各时间点心肌耗氧量变化率与生理盐水组比差异显著(P<0.01)。沙棘总黄酮可显著降低心肌耗氧量,降低率与生理盐水组同时间点相比,30-120分钟差异显著(P<0.01)。From Table 7 and Figure 3, it can be seen that the myocardial oxygen consumption decreased compared with the normal saline group after oral administration of Puhuang extract at 8 mg/kg, and the change rate of myocardial oxygen consumption at each time point from 30 minutes to 120 minutes Compared with normal saline group, the difference was significant (P<0.01). The total flavonoids of seabuckthorn can significantly reduce myocardial oxygen consumption, and the reduction rate is significantly different from that of the normal saline group at the same time point at 30-120 minutes (P<0.01).
蒲黄提取物对犬心肌氧摄取率的影响,见表8和图4The effect of Puhuang extract on the oxygen uptake rate of canine myocardium, see Table 8 and Figure 4
表8蒲黄提取物对犬心肌氧摄取率(%)的影响( x±s,n=5) Table 8 The effect of Puhuang extract on the oxygen uptake rate (%) of canine myocardium ( x±s, n=5)
给药后After administration
组别 指标 给药前Group Index Index Before administration
30min 60min 90min 120min|
生理盐水 x±S 84.6±3.7 86.9±2.6 85.6±1.6 86.8±2.2 89.4±2.5Normal saline x±S 84.6±3.7 86.9±2.6 85.6±1.6 86.8±2.2 89.4±2.5
1ml/kg 变化% 2.9±4.6 1.3±2.9 2.7±2.6 5.7±2.31ml/kg % change 2.9±4.6 1.3±2.9 2.7±2.6 5.7±2.3
沙棘总黄酮 x±S 79.8±5.3 66.2±5.6 65.1±6.1 65.7±2.9 68.5±5.6Seabuckthorn total flavonoids x±S 79.8±5.3 66.2±5.6 65.1±6.1 65.7±2.9 68.5±5.6
24mg/kg 变化% -17.1±4.2*** -18.5±4.2*** -17.5±2.0*** -14.2±3.1*** 24mg/kg Change% -17.1±4.2 *** -18.5±4.2 *** -17.5±2.0 *** -14.2±3.1 ***
蒲黄提取物 x±S 79.6±7.6 62.9±7.2ΔΔ 63.5±7.1ΔΔ 66.2±6.8 70.7±6.9Pollen extract x±S 79.6±7.6 62.9±7.2 ΔΔ 63.5±7.1 ΔΔ 66.2±6.8 70.7±6.9
8mg/kg 变化% -21.1±3.0*** -20.3±3.7*** -16.6±7.5*** -10.9±7.1*** 8mg/kg Change % -21.1±3.0 *** -20.3±3.7 *** -16.6±7.5 *** -10.9±7.1 ***
ΔΔP<0.05,ΔΔΔP<0.01与给药前比较;**P<0.05,***P<0.01与生理盐水组比较 ΔΔ P<0.05, ΔΔΔ P<0.01 compared with before administration; ** P<0.05, *** P<0.01 compared with normal saline group
从表8和图4可以看出,蒲黄提取物灌胃后可显著降低心肌氧摄取率;降低率与生理盐水组同时间点相比,从30分钟至120分钟各时间点差异均非常显著(P<0.01),阳性对照药沙棘总黄酮可显著降低心肌氧摄取率。It can be seen from Table 8 and Figure 4 that Puhuang extract can significantly reduce the myocardial oxygen uptake rate after intragastric administration; compared with the same time point in the normal saline group, the reduction rate is very significant at each time point from 30 minutes to 120 minutes (P<0.01), the positive control drug seabuckthorn total flavonoids can significantly reduce the myocardial oxygen uptake rate.
蒲黄提取物对犬冠脉流量的影响,见表9和图5The effect of Puhuang extract on canine coronary flow, see Table 9 and Figure 5
表9蒲黄提取物对犬冠脉流量(ml/min)的影响( x±s,n=5) Table 9 Effects of Pollen Extract on Canine Coronary Flow (ml/min) ( x±s, n=5)
给药后After administration
组别 指标 给药前Group Index Index Before administration
30min 60min 90min 120min|
生理盐水 x±S 41.4±8.6 41.4±8.3 41.2±8.4 40.8±8.7 41.0±8.2Normal saline x±S 41.4±8.6 41.4±8.3 41.2±8.4 40.8±8.7 41.0±8.2
1ml/kg 变化% 0.2±2.5 -2.4±0.8 -1.6±1.4 -0.7±2.31ml/kg Change % 0.2±2.5 -2.4±0.8 -1.6±1.4 -0.7±2.3
沙棘总黄酮 x±S 44.2±10.2 47.6±10.4 47.2±10.4 47.0±10.6 45.6±10.2Seabuckthorn total flavonoids x±S 44.2±10.2 47.6±10.4 47.2±10.4 47.0±10.6 45.6±10.2
24mg/kg 变化% 8.0±2.2*** 7.0±2.3*** 6.5±0.8***3.3±1.424mg/kg Change % 8.0±2.2 *** 7.0±2.3 *** 6.5±0.8 *** 3.3±1.4
蒲黄提取物 x±S 42.4±10.4 45.8±10.1 44.4±10.7 43.4±10.5 42.6±10.8Pollen Extract x±S 42.4±10.4 45.8±10.1 44.4±10.7 43.4±10.5 42.6±10.8
8mg/kg 变化% 8.6±3.3*** 4.8±2.3** 2.5±1.5 0.3±2.18mg/kg Change % 8.6±3.3 *** 4.8±2.3 ** 2.5±1.5 0.3±2.1
ΔΔP<0.05与给药前比较;**P<0.05,***P<0.01与生理盐水组比较 ΔΔ P<0.05 compared with before administration; ** P<0.05, *** P<0.01 compared with normal saline group
从表9和图5可以看出,蒲黄提取物可增加冠脉流量;增加率与生理盐水组同时间点相比,在30、60分钟差异显著(P<0.05),阳性对照药沙棘总黄酮也可明显增加冠脉流量,作用时间从30-90分钟。It can be seen from Table 9 and Figure 5 that the Puhuang extract can increase the coronary flow rate; compared with the same time point of the normal saline group, the increase rate is significantly different at 30 and 60 minutes (P<0.05), and the positive control drug seabuckthorn total Flavonoids can also significantly increase coronary flow, and the action time is from 30-90 minutes.
由上可见,蒲黄提取物可明显增加麻醉犬冠脉流量,明显降低心肌氧摄取率,显著降低心肌耗氧量,因此可用于制备防治心肌缺血性心血管疾病的药物或食品。It can be seen from the above that the Puhuang extract can significantly increase the coronary flow of anesthetized dogs, significantly reduce the myocardial oxygen uptake rate, and significantly reduce the myocardial oxygen consumption, so it can be used to prepare drugs or food for the prevention and treatment of myocardial ischemic cardiovascular diseases.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031155081A CN1188406C (en) | 2003-02-25 | 2003-02-25 | Cattail pollen extract and preparation process and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031155081A CN1188406C (en) | 2003-02-25 | 2003-02-25 | Cattail pollen extract and preparation process and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1434042A CN1434042A (en) | 2003-08-06 |
CN1188406C true CN1188406C (en) | 2005-02-09 |
Family
ID=27634261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031155081A Expired - Fee Related CN1188406C (en) | 2003-02-25 | 2003-02-25 | Cattail pollen extract and preparation process and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1188406C (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1315856C (en) * | 2004-12-24 | 2007-05-16 | 北京中医药大学 | Extraction and separation method of cattail new glycoside in cattail polleo |
CN1315861C (en) * | 2004-12-24 | 2007-05-16 | 北京中医药大学 | Process for extracting and separating isorhamnetin -3-o-neohesperidoside from cattail pollen |
CN100366630C (en) * | 2005-01-20 | 2008-02-06 | 安徽科创中药天然药物研究所有限责任公司 | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis |
WO2006097940A1 (en) * | 2005-03-14 | 2006-09-21 | Johnson & Johnson Limited | A bandage with enhanced hemostatic effect |
CN101073623B (en) * | 2006-05-18 | 2011-08-10 | 天津天士力制药股份有限公司 | Method for separating and extracting cattail pollen |
CN102949535A (en) * | 2011-08-29 | 2013-03-06 | 苏州同立医药技术有限公司 | Chinese herbal preparation resistant to hyperlipidemia and atherosclerosis and preparation method of Chinese herbal preparation |
CN116077570A (en) * | 2023-02-02 | 2023-05-09 | 河北瑞龙生物科技有限公司 | A kind of preparation method of cattail root extract |
-
2003
- 2003-02-25 CN CNB031155081A patent/CN1188406C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1434042A (en) | 2003-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20040074614A (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa(schenk.)wight, process of making the same, and uses of the same | |
WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
CN1566124A (en) | Cornel extract and use thereof | |
CN105250366B (en) | Dracocephalum moldavica extract and preparation method and application thereof | |
CN1188406C (en) | Cattail pollen extract and preparation process and use thereof | |
CN105687441A (en) | Application of litchi rind polyphenol in medicines for treating hyperglycemia and insulin resistance | |
WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
CN1850161A (en) | Medicine composition for treating pain and preparing method therefor | |
CN101028348A (en) | Chinese medicinal capsule, its production and quality controlling method | |
CN1618441A (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
CN102641347B (en) | Red paeony root extract, as well as preparation and application methods thereof | |
CN1416881A (en) | Medicine composition for treating depression and its prepn | |
CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
CN1291734C (en) | Method for preparing and controlling the quality of Chinese medicinal soft capsule | |
CN1246326C (en) | Pineapple flavonoid glycoside compound and its use | |
CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
CN1876018A (en) | A herbal extract, its preparation method and use | |
CN1634325A (en) | Apocynum extract and extracting method thereof | |
CN101077364A (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
CN1814170A (en) | Medicinal drop pills for treating cardiovascular disease and preparing method | |
CN1279931C (en) | Medicine for treating primary and secondary headache | |
CN1947736A (en) | A preparation method and application of breviscapine injection preparation | |
CN1569184A (en) | Medicinal composition with ginseng and gingko leaf effective portion and its preparation mehtod | |
CN100337654C (en) | Composition of Chinese medicine effective ingredients for treating cardiovascular disease | |
CN1762359A (en) | Alkaloid alkaloids, preparation method and application in pharmacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050209 |